Micro Labs Karnataka’s leading pharma company with a significant diabetic and cardiovascular portfolio is effecting 34 per cent of reduction in cost for certain drugs following the National Pharmaceutical Pricing Authority (NPPA) order of July 10.

The NPPA reduced prices of most of the 108 formulations by 15 to 50 per cent but the prices of some drugs have been cut by as much as 66 per cent. However Micro Labs putting up with a decrease in prices ranging from 4.02 per cent to 34 per cent. The company reduced prices of 26 products said Shrikant Gade, executive vice president supply chain & business development, Micro Labs.

The drugs with the composition of atrovastatin (AVAS) face the highest reduction in cost ranging between 16.79 to 28.40 per cent.

In the hypertensive drug category: amlodipine (Amlong) has taken a 22.62 per cent price cut. Carvedilol (Carvipress) faces a cut of 17.94 per cent. Olmesartan (Olmat) and ramipril (Hopace) have been reduced by 15.82 per cent and 22.33 per cent respectively.

The anti-diabetic drugs like glimerpride (Diapride) has been reduced by 32.51 per cent. Voglibose (Voglinorm) is reduced by 13.35 per cent, Diabose by 10.19 per cent.

The price of sustained release capsules containing diluted isosorbide moninitrate of 60 mg (Nitrofix) cut by 5.17 per cent and uncoated tablets of telmisartan (Arbitel) in 20 mg is priced 6.58 per cent lower. In the case of lisinopril, (Hipril) the company has reduced the price by 6 per cent.

“We have already complied by the NPPA order. The new pricing is implemented and fresh stocks are dispatched to pharmacy trade,” said Gade.

Micro Labs which started operations over 27 years ago has generated net sales of Rs.2,162 crore in fiscal 2013- 2014. In the previous year 2012-13, the company turnover was Rs.1,835 crore. The Bengaluru based active pharmaceutical ingredient and formulation major has 14 speciality divisions with 484 brands. The speciality areas covers from analgesics anti hypertensive to diabetics, lipid lowering agents, dental specialties, anti allergic, anxyiolytics, ophthalmology. dermatology, nutraceutical, phosphate binders, haematinics, hormones, osmotic derivatives and immunosuppressant drugs.

The company has 13 state-of-the-art production plants which have international regulatory approvals from UKMHRA, MCC South Africa, Health Canada, US FDA and Mutual Recognition Procedure, European Union. These are located at Hosur which houses three units, seven units in and around Bengaluru, one unit each at Baddi, Goa and Pondicherry.